Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Revvity (RVTY) stock in plain English

Free brief · no signupStart here
RVTYPublished Nov 12, 2026
Revvity Inc
Healthcare · Diagnostics & Research
Manufactures automated laboratory instruments, genetic testing consumables, and biomedical imaging systems.
Assets:
11,000 employeesStaff across global research, manufacturing, and direct sales offices.
Newborn screening reachSupplies screening tests for millions of babies across over 100 countries.
Proprietary reagent portfolioProduces specialized antibodies and genomic reagents under dedicated biomedical labels.
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

59
OPS ScoreOperating finances
Latest quote
-0.55%$151.59
$16.92B
67.2×
$2.94B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 12, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was RVTY. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Revvity (RVTY) do?

Revvity Inc (RVTY) is a U.S.-listed company in Healthcare (Diagnostics & Research). What it does: Manufactures automated laboratory instruments, genetic testing consumables, and biomedical imaging systems. Provides specialized diagnostic testing tools and laboratory reagents used primarily for drug discovery and newborn. It is worth $16.92B on the market and sold $2.94B over the last year.

Market cap
$16.92B
P/E ratio
67.2×
Annual sales
$2.94B
Sector
Healthcare
Industry
Diagnostics & Research
Brief updated
Nov 12, 2026

Brands and businesses behind RVTY

  • BioLegend: Manufactures antibodies and reagents for biomedical research sold directly to academic and pharmaceutical laboratories.
  • EUROIMMUN: Produces test kits and laboratory automation systems for detecting autoimmune diseases and infectious conditions.
  • Oxford Immunotec: Develops and sells specialized diagnostic blood tests focused on detecting latent tuberculosis infections.
  • Horizon Discovery: Provides gene editing tools and cell lines used by researchers to study genetic functions and diseases.

RVTY’s flags, in plain English

Each flag is a number from Revvity’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 12, 2026.

Stupid Cash

Can pay this year's bills 2.7 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Low debt

Low debt, only 38% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Wide Gross Margin

Gross margin of 49.2% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Priced for Perfection

Priced at 67.2 times its yearly profit, so a lot of growth is already expected. The share price already assumes strong results, so news that is merely good can still send it down.

1 more risk note open with the free trial. Try it free for 7 days.

Questions about RVTY

How big is Revvity?

Revvity’s market cap is $16.92B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $2.94B: what customers paid the company over the last year, before any costs.

What is RVTY’s P/E ratio?

RVTY’s P/E ratio is 67.2×. Investors pay about 67.2 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with RVTY?

Reduced research spending by biotechnology and pharmaceutical customers lowers order volumes for instruments and consumable testing kits. That is one risk on Revvity’s card. Its first risk flag is Priced for Perfection, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Revvity’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. RVTY’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card